News Sentiment

XERS sentiment intelligence

Xeris Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 8.34 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

91/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+0.7% over one week, +22.8% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Enterprise value to revenue forward of Xeris Biopharma Holdings, Inc. – NASDAQ:XERS

Market Reaction

Balanced read

54/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 91/100 classification
One-week reaction 0.7% Price digesting
Trend fit Trend inactive 22.8% over four weeks
Fair value 94.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 40
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
TradingView 8
Business Wire 6
Market source 5
MT Newswires 4
Investing.com Canada 4
Investing.com 3
Sahm 2

Event Lens

What the news is about

Classified themes
Market update 48
Earnings 4
Capital return 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 54
Investing.com Direct company coverage

Xeris Biopharma CFO Steven Pieper sells $383,176 in company stock

Xeris Biopharma's CFO, Steven Pieper, sold 45,000 shares of company stock for approximately $383,176 in early July through a pre-arranged trading plan. This sale occurred after the stock delivered a 78% return over the past year, and InvestingPro data suggests the stock is curren

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 11:11
Source
Investing.com
TradingView Direct company coverage

Price to earnings forward of Xeris Biopharma Holdings, Inc. – NASDAQ:XERS

The article focuses on the "Price to earnings forward" metric for Xeris Biopharma Holdings, Inc. (NASDAQ: XERS). It appears to be a financial data page from TradingView, providing an overview of the company's financials for investors and analysts interested in its valuation.

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 02:09
Source
TradingView
Investing.com Canada Direct company coverage

Xeris Biopharma CFO Steven Pieper sells $383,176 in company stock By Investing.com

Steven Pieper, the CFO of Xeris Biopharma Holdings Inc. (NASDAQ:XERS), sold a total of 45,000 shares of company stock for approximately $383,176 in early July, under a pre-arranged trading plan. This sale follows a strong 78% return for the stock over the past year. After these t

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 21:41
Source
Investing.com Canada
Investing.com Canada Direct company coverage

Form 4 Xeris Pharmaceuticals Inc For: 7 July By Investing.com

This article reports on a Form 4 filing for Xeris Pharmaceuticals Inc. on July 7, 2026. Form 4s are SEC filings used to report changes in beneficial ownership of a company's stock by insiders. The article indicates that Xeris Pharmaceuticals Inc. (XERS) stock was up 6.93% at the

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 21:41
Source
Investing.com Canada
Investing.com Canada Direct company coverage

Form 144 XERIS BIOPHARMA HOLDINGS For: 7 July By Investing.com

Investing.com reports the filing of Form 144 for Xeris Biopharma Holdings (XERS) on July 7. The article provides the company's stock performance and states that the information is © Reuters. This brief notice is part of a larger financial news update.

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 20:41
Source
Investing.com Canada
Stock Titan Direct company coverage

Steven Pieper sells 17,400 shares for $147,900 — XERS

A recent SEC Form 144 filing indicates that Steven Pieper sold 17,400 shares of Xeris Biopharma Holdings, Inc. (XERS) common stock for a total of $147,900 on July 6, 2026. This transaction was executed under a 10b5-1 trading plan. The filing also notes prior issuer transactions f

Tone
Negative 41/100
Event
Market update
Published
07 Jul 2026 20:41
Source
Stock Titan
Stock Titan Direct company coverage

Xeris Biopharma (XERS) officer sells 45,000 shares under Rule 10b5-1 plan

Steven Pieper, an officer at Xeris Biopharma Holdings (XERS), sold 45,000 shares of common stock over two days, July 6-7, 2026, for a total of $383,176. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025. After these transactions, Piep

Tone
Negative 32/100
Event
Market update
Published
07 Jul 2026 20:41
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBITDA forward of Xeris Biopharma Holdings, Inc. – NASDAQ:XERS

This article provides financial data for Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), specifically focusing on its enterprise value to EBITDA forward metric. It appears to be a stub or data-focused page from TradingView, indicating that the market was closed at the time of acce

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 23:39
Source
TradingView
Stock Titan Direct company coverage

Insider reports 400-share purchase and 17,000 RSUs | XERS SEC Filing - Form 144

A recent SEC Form 144 filing for Xeris Biopharma Holdings, Inc. (XERS) reported insider transactions, including an open-market purchase of 400 common shares on May 17, 2017, and an issuance of 17,000 restricted stock units (RSUs) on December 28, 2017. The filing's header date is

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 20:11
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBIT forward of Xeris Biopharma Holdings, Inc. – NASDAQ:XERS

This article provides financial data for Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), specifically focusing on its enterprise value to EBIT forward. It indicates market details such as "Market closed" and "No trades," suggesting the data presented might be static or from a non-

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 17:11
Source
TradingView
TradingView Direct company coverage

Price to book forward of Xeris Biopharma Holdings, Inc. – NASDAQ:XERS

This article provides the "Price to book forward" for Xeris Biopharma Holdings, Inc. (NASDAQ: XERS). It is a financial data point displayed within the TradingView platform, showing the value and change percentage for a specific period. The content is primarily a presentation of t

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 20:09
Source
TradingView
TradingView Direct company coverage

Price to book forward of Xeris Biopharma Holdings, Inc. – LSE:0A8E

This article provides limited financial data for Xeris Biopharma Holdings, Inc. (LSE:0A8E), specifically its "Price to book forward" metric. The content primarily focuses on the company's financial overview within the TradingView platform and includes extensive navigation and cop

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 01:41
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Xeris Biopharma Holdings, Inc. – NASDAQ:XERS

This article provides financial information for Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), specifically focusing on its forward price to sales ratio. The content is presented within the TradingView platform, offering various market analysis tools and data provided by ICE Data

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 12:40
Source
TradingView
Stock Titan Direct company coverage

If You Invested $1,000 in Xeris Biopharma Holdings (XERS)

This article analyzes the historical performance of investing $1,000 in Xeris Biopharma Holdings (XERS) over various periods, showing significant returns for investments made one and five years ago, but a loss for investments since its 2018 trading start. It details the company's

Tone
Positive 66/100
Event
Market update
Published
04 Jul 2026 09:41
Source
Stock Titan
Sahm Direct company coverage

Xeris Biopharma Holdings (XERS) Patent Win Puts Its Valuation Back In Focus

Xeris Biopharma Holdings (XERS) has garnered attention due to a patent win for its Keveyis product, potentially extending protection until 2039, and recent board and leadership changes. Despite being considered 25.7% undervalued at its current price of $8.28 against a fair value

Tone
Positive 70/100
Event
Market update
Published
03 Jul 2026 10:10
Source
Sahm
Business Wire Direct company coverage

CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Xeris Biopharma Holdings, Inc. announced that its Compensation Committee granted non-qualified stock options and restricted stock units for an aggregate of 221,323 shares to 47 new employees. These inducement grants are made under Nasdaq Listing Rule 5635(c)(4) and are intended t

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 02:41
Source
Business Wire
GuruFocus Direct company coverage

Beth Hecht Sells 16,666 Shares of Xeris Biopharma Holdings Inc (XERS)

Beth Hecht, an insider at Xeris Biopharma Holdings Inc (XERS), sold 16,666 shares of the company on July 1, 2026, bringing her total ownership to 1,161,128 shares. This sale contributes to a pattern of 24 insider sells and no buys over the past year. The stock, trading at $8.03,

Tone
Negative 30/100
Event
Market update
Published
02 Jul 2026 23:41
Source
GuruFocus
Investing.com Canada Direct company coverage

Form 4 Xeris Pharmaceuticals Inc For: 2 July By Investing.com

The article reports on a Form 4 filing for Xeris Pharmaceuticals Inc. on July 2. Form 4 filings detail changes in beneficial ownership of company securities by insiders. The article also provides various financial market data and news headlines.

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 22:41
Source
Investing.com Canada
Stock Titan Direct company coverage

Xeris Biopharma (XERS) director Nerissa Kreher listed as reporting person on Form 3

Xeris Biopharma Holdings, Inc. director Nerissa Kreher has been listed as a reporting person on a recently filed Form 3. This initial statement of beneficial ownership indicates no reported buying, selling, acquiring, disposing, or other share transactions, with all transaction c

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 22:09
Source
Stock Titan
Stock Titan Direct company coverage

Director at Xeris Biopharma (NASDAQ: XERS) receives stock and options grants

Xeris Biopharma director Nerissa Kreher received equity-based compensation including 33,582 restricted stock units and stock options for 37,910 shares with an exercise price of $8.00. Both grants vest over three years, contingent on her continued service on the board. This Form 4

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:41
Source
Stock Titan
Stock Titan Direct company coverage

Planned sale: Xeris Biopharma (XERS) officer trades 16,666 shares

Xeris Biopharma Holdings, Inc. officer Beth Hecht reported selling 16,666 shares of common stock at a weighted average price of $8.0319 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025. After the sale, Hecht retains

Tone
Negative 38/100
Event
Market update
Published
02 Jul 2026 21:41
Source
Stock Titan
Market source Direct company coverage

Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Xeris Biopharma Holdings, Inc. announced that its Compensation Committee granted restricted stock units for 221,323 shares of common stock to 47 new employees on July 1, 2026. These grants were made under Xeris' Inducement Equity Plan, exclusively for new hires to incentivize emp

Tone
Positive 61/100
Event
Market update
Published
02 Jul 2026 20:05
Source
Market source
Stock Titan Direct company coverage

[144] Xeris Biopharma Holdings, Inc. SEC Filing

This article reports on a Form 144 SEC filing by Xeris Biopharma Holdings, Inc. (XERS), indicating an intent to sell 120,000 shares of common stock with an aggregate market value of $950,400.00. The securities were acquired on January 29, 2024, as Restricted Stock Units from the

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:41
Source
Stock Titan
Finviz Direct company coverage

XERS - Xeris Biopharma Holdings Inc Options

This page provides an extensive overview of Xeris Biopharma Holdings Inc (XERS), including its last closing price, financial metrics, valuation ratios, and performance indicators. It also lists key statistics like market capitalization, income, sales, EPS, insider ownership, inst

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 12:39
Source
Finviz